Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Increases By 8.4%

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 213,500 shares, a growth of 8.4% from the March 31st total of 197,000 shares. Based on an average daily volume of 142,800 shares, the days-to-cover ratio is presently 1.5 days.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ANIP. Guggenheim reaffirmed a "buy" rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a "buy" rating in a report on Monday, March 4th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an "overweight" rating and a $80.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $80.00.

Insider Buying and Selling

In related news, COO Muthusamy Shanmugam sold 16,809 shares of ANI Pharmaceuticals stock in a transaction on Friday, April 19th. The shares were sold at an average price of $65.17, for a total value of $1,095,442.53. Following the sale, the chief operating officer now owns 782,620 shares of the company's stock, valued at approximately $51,003,345.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Muthusamy Shanmugam sold 16,809 shares of the firm's stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $65.17, for a total value of $1,095,442.53. Following the transaction, the chief operating officer now directly owns 782,620 shares of the company's stock, valued at $51,003,345.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP James G. Marken sold 24,338 shares of the company's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.37, for a total transaction of $1,615,313.06. Following the sale, the senior vice president now directly owns 124,492 shares of the company's stock, valued at approximately $8,262,534.04. The disclosure for this sale can be found here. In the last 90 days, insiders sold 156,803 shares of company stock valued at $10,363,466. 12.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its holdings in ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company's stock worth $30,000 after purchasing an additional 248 shares during the period. BluePath Capital Management LLC acquired a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $34,000. Pacer Advisors Inc. purchased a new position in ANI Pharmaceuticals in the fourth quarter worth approximately $41,000. AJOVista LLC acquired a new position in ANI Pharmaceuticals during the 4th quarter worth approximately $58,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $132,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Up 0.8 %

Shares of ANIP traded up $0.50 during trading on Tuesday, reaching $66.00. 114,040 shares of the company traded hands, compared to its average volume of 135,155. The stock has a 50-day simple moving average of $65.91 and a 200-day simple moving average of $58.93. The stock has a market cap of $1.39 billion, a PE ratio of 77.98 and a beta of 0.79. ANI Pharmaceuticals has a twelve month low of $37.40 and a twelve month high of $70.81. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The company had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. On average, analysts anticipate that ANI Pharmaceuticals will post 3.55 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.